Literature DB >> 33611665

Different strategies in marking axillary lymph nodes in breast cancer patients undergoing neoadjuvant medical treatment: a systematic review.

Vivian Man1, Ava Kwong2.   

Abstract

BACKGROUND: Marking of cytology-proven metastatic axillary lymph node in breast cancer patients before neoadjuvant treatment and its subsequent surgical retrieval have been shown to reduce the false-negative rate of sentinel lymph node biopsy. A systematic review was performed to evaluate different strategies in nodal marking and localization.
METHODS: PubMed, Embase, EBSCOhost, and the Cochrane library literature databases were searched systematically to address the identification rate and retrieval rate of marked axillary lymph nodes. Studies were eligible if they performed nodal marking before neoadjuvant treatment, followed by selective extirpation of these marked axillary lymph nodes in definitive surgery
RESULTS: Fifteen studies with a total of 703 patients were included. Index axillary lymph nodes were marked by clips or tattooed prior to the commencement of neoadjuvant treatment. In our pooled analysis, eighty-eight percent of the clipped nodes and ninety-seven percent of the tattooed nodes were successfully retrieved. Among these patients, seventy-seven percent of these marked axillary lymph nodes were also sentinel lymph nodes.
CONCLUSION: Marking and selectively removing cytology-proven metastatic axillary lymph nodes after neoadjuvant treatment is feasible. An acceptably high nodal retrieval rate could be achieved using various methods of nodal marking and localization techniques.

Entities:  

Keywords:  Breast cancer; Neoadjuvant therapy; Nodal marking; Targeted axillary dissection

Year:  2021        PMID: 33611665     DOI: 10.1007/s10549-021-06118-6

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  32 in total

1.  Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.

Authors:  Jean-Francois Boileau; Brigitte Poirier; Mark Basik; Claire M B Holloway; Louis Gaboury; Lucas Sideris; Sarkis Meterissian; Angel Arnaout; Muriel Brackstone; David R McCready; Stephen E Karp; Isabelle Trop; Andre Lisbona; Frances C Wright; Rami J Younan; Louise Provencher; Erica Patocskai; Atilla Omeroglu; Andre Robidoux
Journal:  J Clin Oncol       Date:  2014-12-01       Impact factor: 44.544

2.  Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes.

Authors:  Brittany L Murphy; Courtney N Day; Tanya L Hoskin; Elizabeth B Habermann; Judy C Boughey
Journal:  Ann Surg Oncol       Date:  2018-05-21       Impact factor: 5.344

3.  Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial.

Authors:  Abigail S Caudle; Wei T Yang; Elizabeth A Mittendorf; Daliah M Black; Rosa Hwang; Brian Hobbs; Kelly K Hunt; Savitri Krishnamurthy; Henry M Kuerer
Journal:  JAMA Surg       Date:  2015-02       Impact factor: 14.766

Review 4.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Authors:  Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz
Journal:  Lancet       Date:  2014-02-14       Impact factor: 79.321

5.  Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.

Authors:  Thorsten Kuehn; Ingo Bauerfeind; Tanja Fehm; Barbara Fleige; Maik Hausschild; Gisela Helms; Annette Lebeau; Cornelia Liedtke; Gunter von Minckwitz; Valentina Nekljudova; Sabine Schmatloch; Peter Schrenk; Annette Staebler; Michael Untch
Journal:  Lancet Oncol       Date:  2013-05-15       Impact factor: 41.316

6.  Neoadjuvant treatment of breast cancer.

Authors:  A M Thompson; S L Moulder-Thompson
Journal:  Ann Oncol       Date:  2012-09       Impact factor: 32.976

7.  Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.

Authors:  Judy C Boughey; Vera J Suman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Henry M Kuerer; Monet Bowling; Teresa S Flippo-Morton; David R Byrd; David W Ollila; Thomas B Julian; Sarah A McLaughlin; Linda McCall; W Fraser Symmans; Huong T Le-Petross; Bruce G Haffty; Thomas A Buchholz; Heidi Nelson; Kelly K Hunt
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

8.  Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).

Authors:  Judy C Boughey; Karla V Ballman; Huong T Le-Petross; Linda M McCall; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; Eric C Feliberti; Kelly K Hunt
Journal:  Ann Surg       Date:  2016-04       Impact factor: 12.969

9.  Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.

Authors:  Abigail S Caudle; Wei T Yang; Savitri Krishnamurthy; Elizabeth A Mittendorf; Dalliah M Black; Michael Z Gilcrease; Isabelle Bedrosian; Brian P Hobbs; Sarah M DeSnyder; Rosa F Hwang; Beatriz E Adrada; Simona F Shaitelman; Mariana Chavez-MacGregor; Benjamin D Smith; Rosalind P Candelaria; Gildy V Babiera; Basak E Dogan; Lumarie Santiago; Kelly K Hunt; Henry M Kuerer
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

Review 10.  Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review.

Authors:  Melissa Pilewskie; Monica Morrow
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

View more
  3 in total

1.  Improved false-negative rates using a novel patient selection flowchart in initially biopsy-proven node-positive breast cancer undergoing blue-dye alone guided sentinel lymph node biopsy after neoadjuvant chemotherapy.

Authors:  Minyan Chen; Shengmei Li; Meng Huang; Jingjing Guo; Xuan Huang; Wenhui Guo; Lili Chen; Yuxiang Lin; Lisa Jacobs; Chuan Wang; Fangmeng Fu
Journal:  Breast Cancer Res Treat       Date:  2022-09-13       Impact factor: 4.624

2.  Pathological examination of breast cancer samples before and after neoadjuvant therapy: recommendations from the Italian Group for the Study of Breast Pathology - Italian Society of Pathology (GIPaM-SIAPeC).

Authors:  Nicola Fusco; Antonio Rizzo; Leopoldo Costarelli; Alfredo Santinelli; Bruna Cerbelli; Cristian Scatena; Ettore Macrì; Francesca Pietribiasi; Giulia d'Amati; Anna Sapino; Isabella Castellano
Journal:  Pathologica       Date:  2022-04-13

3.  Pathology after neoadjuvant treatment - How to assess residual disease.

Authors:  Giuseppe Viale; Nicola Fusco
Journal:  Breast       Date:  2021-11-16       Impact factor: 4.254

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.